If you’re an enterprise AE carrying a seven‑figure number into greenfield or whitespace Fortune 1000 accounts, you don’t have time for AI “parlor tricks." You need AI to do three things, fast. Learn about it.
You can fix your top 10 account plans in one afternoon if you stop asking AI the wrong questions. Feed as much information to AI to get the best results and fine tune your prompts. Ask for sales plays not information.
Your AI is confidently making stuff up about your accounts. You’re not crazy. Last month I watched an Enterprise AE build a “killer” account plan for a greenfield Fortune 500 logo in the automotive sector and reach out to an exec about winning a race that hadn't taken place yet.
Discover how enterprise tech sellers can turn the $44.8 billion Unilever–McCormick Foods merger into real sales opportunity. This guide shows how the new “global flavour powerhouse” reshapes technology priorities, budgets, and org charts—and how savvy sellers can align solutions to emerging integration, data, and supply chain challenges.
When a legacy U.S. beauty house and a fast-rising Spanish fragrance powerhouse start talking merger, every enterprise technology seller with exposure to retail, CPG, beauty, or global commerce should sit up and pay attention. The emerging Estée Lauder–Puig deal checks every box for a high‑impact transformation: scale, geography, channel mix, portfolio overlap, and deep family ownership dynamics.
This CoStart blog post gives Strategic AEs a practical, six-week ABS playbook for CoStar, a $3.25B real estate data and marketplace leader. It covers stakeholder mapping, research angles, multi-threaded outreach, and ready-to-use messaging that helps book more first meetings and build internal champions in complex Fortune 1000 accounts.
Explore how Capital One’s recent AI, data, and M&A moves are reshaping its technology roadmap—and why that’s great news for savvy SaaS sellers. This post exposes where fresh budget and urgency are emerging, who to target, and exactly how to talk to them like an insider.
Gilead Sciences’ agreement to acquire Arcellx is a high‑stakes bet on next‑generation cell therapy that deepens its oncology franchise, reshapes competition in multiple myeloma, and opens new pathways for technology and SaaS selling into a more complex, integrated global enterprise.
